First gastroesophageal cancer patients enrolled in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025
Solna, Sweden, March 26, 2024. Affibody AB (“Affibody”) today announced that the first patients with gastroesophageal cancer have been dosed in a Phase 2 clinical basket study of the PET imaging agent 68Ga-ABY-025 (“HER2 PET”) for non-invasive quantification of HER2-status in solid tumors. ABY-025 is based on an Affibody® molecule that binds strongly to HER2 – a cell surface protein implicated in several forms of cancer. The high affinity and rapid clearance of ABY-025 from blood and normal tissue allows HER2 assessment within hours.Gastroesophageal cancer continues to present global